On January 21, a Northern District of California Court denied Plaintiff Tevra Brands LLC’s (“Tevra’s”) Motion for a New Trial, after a Jury found ...
Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted challenges in GARDASIL sales in ...
Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...
Investors hammered Merck stock Tuesday after the company beat fourth-quarter expectations, but delivered a light 2025 outlook.
Public awareness will also be key to addressing the problem. Many pet owners do not know that their routine flea treatments affect wildlife. Small changes could help reduce this impact. For example, ...